Klotho Neurosciences logo

Klotho Neurosciences(NASDAQ) KLTOW

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)+336%
5 YearN/A
1 Year+203%
1 Month+205%
N/A
Klotho Neurosciences last closing stock price
MetricPriceDate
Last closeUSD 0.612026-10-13
Klotho Neurosciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+22.02%USD 0.502026-10-06
1 month+205.2%USD 0.202026-09-11
3 month+220.94%USD 0.192026-07-15
Year to date+536.18%USD 0.102025-12-31
1 year+202.78%USD 0.202025-10-13
3 year+745.01%USD 0.072023-10-12
Since inception+335.79%USD 0.142022-04-29

Klotho Neurosciences Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$21.77M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

N/A

KLTOW News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Klotho Neurosciences

Klotho Neurosciences, Inc. is a biopharmaceutical company dedicated to developing innovative medical treatments for severe illnesses, including cancer and neurological disorders. The company focuses on gene therapy candidates aimed at addressing conditions such as Alzheimer's disease and amyotrophic lateral sclerosis (ALS).

Products and Services
  • Gene therapy candidate AMI-101 for Alzheimer's disease
  • Gene therapy candidate AMI-202 for ALS management
  • Research and development of treatments for various severe illnesses
Growth Outlook
  • Significant investment in research and development, totaling over $400,000 in Q2 2026
  • Strong cash position with over $9 million in cash and equivalents as of June 2026
  • Potential for market expansion as gene therapy gains traction in the healthcare sector
Financial Highlights
  • Net income of -$3.68 million reported in Q2 2026
  • Operating expenses of approximately $5.49 million in Q2 2026
  • Current ratio of 10.09 indicates strong liquidity position
Klotho Neurosciences, Inc. is positioned in the biotechnology sector, focusing on groundbreaking therapies that address critical health challenges. The company's commitment to research and development is evident in its substantial investments, which are essential for advancing its innovative product pipeline. The financial data reflects a challenging operating environment, with significant net losses reported in recent quarters. However, the strong liquidity position, indicated by a current ratio of 10.09, provides a buffer for ongoing operations and development efforts. As the healthcare landscape evolves, Klotho Neurosciences, Inc. may capitalize on the growing demand for effective gene therapies, potentially leading to future growth and market opportunities.
AI Generated • Sep 18, 2026

Industry

Biotechnology

Sector

Health Care

Headquarters

Omaha, NE 68144, US

KLTOW Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-67.62%

Return on Capital

-75.51%

Return on Assets

-33.48%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$18.67M

EBITDA

-$23.01M

Operating Cash Flow

-$13.90M

Capital Expenditure

-$682.85K

Free Cash Flow

-$14.58M

Cash & ST Invst.

$9.34M

Total Debt

$297.97K

Klotho Neurosciences Performance Analysis

Klotho Neurosciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Klotho Neurosciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3059.5%
Q42025-12-3162.6%
Q12026-03-31-724.2%
Q22026-06-3080.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

3

N/A

Net Income

-$3.69M

+10.0%

EBITDA

-$5.49M

-190.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$9.34M

+10.8%

Total Debt

$297.97K

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$297.97K

N/A

Return on Assets

-33.48%

N/A

Return on Invested Capital

-29.26%

N/A

Free Cash Flow

-$6.88M

-249.4%

Operating Cash Flow

-$6.56M

-233.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ALECAlector, Inc.
$1.87-10.10%
BDTXBlack Diamond Therapeutics, Inc.
$1.68-5.08%
CARMCarisma Therapeutics, Inc.
$0.00+0.00%
DAICCID HoldCo, Inc.
$1.61-5.29%

Trending Stocks

Symbol / CompanyPricePrice Chg
CIFRCipher Digital
$11.34-12.77%
BMBLBumble
$5.95+56.58%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$37.42+0.62%
INTCIntel
$102.81+1.44%

Questions About KLTOW

What is the current price of Klotho Neurosciences?

Klotho Neurosciences is trading at N/A per share.

What is the 52-week range for Klotho Neurosciences?

Over the past 52 weeks, Klotho Neurosciences has traded between N/A and N/A.

How much debt does Klotho Neurosciences have?

Klotho Neurosciences total debt is unavailable.

How much cash does Klotho Neurosciences have on hand?

Klotho Neurosciences does not have cash on hand data available.

What is Klotho Neurosciences’s dividend yield?

Klotho Neurosciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services